Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2U10EY011751 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Eye Institute (NEI) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This pilot study is being conducted as a prelude to a randomized trial to compare levodopa/carbidopa plus patching versus patching alone. The purpose of the pilot study is to demonstrate recruitment potential, to provide prospective data on the tolerability of levodopa as a treatment for amblyopia, to provide limited data on its safety, to provide limited data on it's efficiency, and to provide data to assist in selecting a dose to use in a subsequent phase 3 randomized trial. In addition, this study will provide the opportunity for investigators to gain experience in using levodopa prior to a randomized trial.
Amblyopia is the most common cause of monocular visual impairment in both children and young and middle-aged adults. Both patching and atropine are accepted treatment modalities for the management of moderate amblyopia in children. Despite best efforts with conventional amblyopia treatment, many older children and teenagers with amblyopia fail to achieve normal visual acuity in the amblyopic eye. In a previous PEDIG study (ATS3) where children 7 to 13 years old were treated with atropine and patching, only 36% of the children with moderate amblyopia and only 23% of the children with severe amblyopia achieved 20/40 or better acuity.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Lower Dose (3-1) levodopa/carbidopa | Active Comparator | Oral levodopa 0.51 mg/kg tid with carbidopa 0.17 mg/kg tid (3 to 1 formulation) combined with 2 hours of daily patching, with a rapid taper of medication before a primary outcome exam 9 weeks after starting medication. |
|
| Higher Dose (4.5-1) levodopa/carbidopa | Active Comparator | Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid (approximately 4.5 to 1 formulation) combined with 2 hours of daily patching, with a rapid taper of medication before a primary outcome exam 9 weeks after starting medication. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| levodopa/carbidopa | Drug | Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid (approximately 4.5 to 1 formulation) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Distribution of Amblyopic Eye Visual Acuity Letter Scores at 9 Weeks After Starting Levodopa | Visual acuity was measured with the electronic early treatment diabetic retinopathy study (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. Letter scores are presented as Snellen Equivalents for presentation (i.e. 20/20 includes those with letter scores between 83 and 87 letters, 20/25 includes those with letter scores between 78 to 82 letters, etc.). | 9 weeks after starting levodopa |
| Mean Amblyopic Eye Visual Acuity Letter Scores at 9 Weeks After Starting Levodopa | Visual acuity was measured with the electronic early treatment diabetic retinopathy study (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. | 9 weeks after starting levodopa |
| Distribution of Change in Amblyopic Eye Visual Acuity Scores at 9 Weeks After Starting Levodopa | Visual acuity was measured with the electronic early treatment diabetic retinopathy study (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 the best. A difference was calculated as the difference in letters between baseline and outcome with positive difference indicating improvement in acuity. | baseline to 9 weeks |
| Mean Change in Amblyopic Eye Visual Acuity Letter Scores at 9 Weeks After Starting Levodopa | Visual acuity was measured with the electronic early treatment diabetic retinopathy study (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 the best. A difference was calculated as the difference in letters between baseline and outcome with positive difference indicating improvement in acuity. | baseline to 9 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Distribution of Amblyopic Eye Visual Acuity Letter Scores at 4 Weeks After Enrollment | Visual acuity was measured with the electronic early treatment diabetic retinopathy study (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 the best. Letter scores are presented as Snellen Equivalents for presentation (i.e. 20/20 includes those with letter scores between 83 and 87 letters, 20/25 includes those with letter scores between 78 to 82 letters, etc.). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Myopia more than -6.00 D (spherical equivalent) in either eye.
Current vision therapy or orthoptics
Ocular cause for reduced visual acuity
• nystagmus per se does not exclude the subject if the above visual acuity criteria are met
Prior intraocular or refractive surgery
History of narrow-angle glaucoma
Strabismus surgery planned within 16 weeks
Known allergy to levodopa-carbidopa
History of dystonic reactions
Current requirement to take oral iron supplements including multivitamins containing iron during the 8 weeks of treatment with levodopa-carbidopa
Current use of antihypertensive, anti-depressant medications, phenothiazines, butyrophenones, risperidone and isoniazid, non-specific monoamine oxidase inhibitors
Current use of medication for the treatment of attention deficit hyperactivity disorder
Known gastrointestinal or liver disease
History of melanoma
Known psychological problems
Known skin reactions to patch or bandage adhesives
Prior levodopa treatment
Current treatment with topical atropine
Females who are pregnant, lactating, or intending to become pregnant within the next 16 weeks.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Michael X. Repka, M.D. | Wilmer Eye Institute | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Wilmer Eye Institute | Baltimore | Maryland | 21287 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 20837811 | Result | Repka MX, Kraker RT, Beck RW, Atkinson CS, Bacal DA, Bremer DL, Davis PL, Gearinger MD, Glaser SR, Hoover DL, Laby DM, Morrison DG, Rogers DL, Sala NA, Suh DW, Wheeler MB; Pediatric Eye Disease Investigator Group. Pilot study of levodopa dose as treatment for residual amblyopia in children aged 8 years to younger than 18 years. Arch Ophthalmol. 2010 Sep;128(9):1215-7. doi: 10.1001/archophthalmol.2010.178. No abstract available. |
Not provided
Not provided
At enrollment, subjects were required to have been treated with at least 2 hours of patching per day of daily patching and while on that therapy, have had stable visual acuity (5 letters or one logMAR line of improvement since a previous visit at least 8 weeks earlier)
Eligibility criteria included age 8 to <18 years, best-corrected visual acuity in the amblyopic eye between 67 and 18 letters inclusive measured with E-ETDRS, fellow eye best-corrected visual acuity of 78 letters or better, and the presence or history of strabismus and/or anisometropia.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Lower Dose 0.51 mg Levodopa/Carbidopa | Oral levodopa 0.51 mg/kg tid with carbidopa 0.17 mg/kg tid combined with 2 hours of daily patching, with a rapid taper of medication before a primary outcome exam. |
| FG001 | Higher Dose 0.76 mg Levodopa/Carbidopa | Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid combined with 2 hours of daily patching, with a rapid taper of medication before a primary outcome exam. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Lower Dose 0.51 mg Levodopa/Carbidopa | Oral levodopa 0.51 mg/kg tid with carbidopa 0.17 mg/kg tid combined with 2 hours of daily patching, with a rapid taper of medication before a primary outcome exam. |
| BG001 | Higher Dose 0.76 mg Levodopa/Carbidopa |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Distribution of Amblyopic Eye Visual Acuity Letter Scores at 9 Weeks After Starting Levodopa | Visual acuity was measured with the electronic early treatment diabetic retinopathy study (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. Letter scores are presented as Snellen Equivalents for presentation (i.e. 20/20 includes those with letter scores between 83 and 87 letters, 20/25 includes those with letter scores between 78 to 82 letters, etc.). | Posted | Number | participants | 9 weeks after starting levodopa |
|
Up to 6 months
Adverse events were systematically collected at each office visit (4wks post-enrollment, 9 wks after starting levodopa, and 10 wks after stopping levodopa) and on each phone call (2wks and 7wks post-enrollment)throughout the study.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Lower Dose 0.51 mg Levodopa/Carbidopa | Oral levodopa 0.51 mg/kg tid with carbidopa 0.17 mg/kg tid combined with 2 hours of daily patching, with a rapid taper of medication before a primary outcome exam. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Headache | General disorders | Systematic Assessment |
Without a patching-only control group, no conclusions can be made regarding efficacy, safety, or side effects with this treatment. Placebo controlled trial is needed to see if levodopa can augment occlusion therapy in the treatment of amblyopia.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Raymond Kraker, MSPH | Jaeb Center for Health Research | 813-875-8690 | pedig@jaeb.org |
Not provided
| ID | Term |
|---|---|
| D000550 | Amblyopia |
| ID | Term |
|---|---|
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D014786 | Vision Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C009265 | carbidopa, levodopa drug combination |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| patching | Device | 2 hours daily patching |
|
|
| levodopa/carbidopa | Drug | Oral levodopa 0.51mg/kg tid with carbidopa 0.17 mg/kg tid (3 to 1 formulation) |
|
| Tolerability of Study Medication-Adverse Event Reporting |
Number of adverse events reported throughout entire study. |
| 24 weeks |
| 4 weeks after enrollment |
| Mean Amblyopic Eye Visual Acuity Letter Scores at 4 Weeks Post Enrollment | Visual acuity was measured with the electronic early treatment diabetic retinopathy study (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 the best. | 4 weeks after enrollment |
| Distribution of Amblyopic Eye Visual Acuity Letter Scores at 10 Weeks After Stopping Levodopa | Visual acuity was measured with the electronic early treatment diabetic retinopathy study (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 the best. Letter scores are presented as Snellen Equivalents for presentation (i.e. 20/20 includes those with letter scores between 83 and 87 letters, 20/25 includes those with letter scores between 78 to 82 letters, etc.). | 10 weeks after stopping levodopa |
| Mean Amblyopic Eye Visual Acuity Letter Scores at 10 Weeks After Stopping Levodopa | Visual acuity was measured with the electronic early treatment diabetic retinopathy study (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 the best. | 10 weeks after stopping levodopa |
| Distribution of Change in Amblyopic Eye Visual Acuity Scores at 4 Weeks Post Enrollment | Visual acuity was measured with the electronic early treatment diabetic retinopathy study (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 the best. A difference was calculated as the difference in letters between baseline and outcome with positive difference indicating improvement in acuity. | enrollment to 4 weeks |
| Mean Change in Amblyopic Eye Visual Acuity Letter Scores at 4 Weeks Post Enrollment | Visual acuity was measured with the electronic early treatment diabetic retinopathy study (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 the best. A difference was calculated as the difference in letters between baseline and outcome with positive difference indicating improvement in acuity. | enrollment to 4 weeks |
| Distribution of Change in Amblyopic Eye Visual Acuity Scores at 10 Weeks After Stopping Levodopa | Visual acuity was measured with the electronic early treatment diabetic retinopathy study (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters. A difference was calculated as the difference in letters between baseline and outcome with positive difference indicating improvement in acuity. | baseline to 10 weeks after stopping levodopa |
| Mean Change in Amblyopic Eye Visual Acuity Letter Scores at 10 Weeks After Stopping Levodopa | Visual acuity was measured with the electronic early treatment diabetic retinopathy study (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 the best. A difference was calculated as the difference in letters between baseline and outcome with positive difference indicating improvement in acuity. | baseline to 10 weeks after stopping levodopa |
Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid combined with 2 hours of daily patching, with a rapid taper of medication before a primary outcome exam. |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Age, Customized | Age at enrollment in years | Number | participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Cause of Amblyopia | Number | participants |
|
| Distance Visual Acuity in Amblyopic Eye | Visual acuity was measured with the electronic early treatment diabetic retinopathy study (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. Letter scores are presented as Snellen Equivalents for presentation (i.e. 20/20 includes those with letter scores between 83 and 87 letters, 20/25 includes those with letter scores between 78 to 82 letters, etc.). | Number | participants |
|
| Distance Visual Acuity in Fellow Eye | Visual acuity was measured with the electronic early treatment diabetic retinopathy study (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. Letter scores are presented as Snellen Equivalents for presentation (i.e. 20/20 includes those with letter scores between 83 and 87 letters, 20/25 includes those with letter scores between 78 to 82 letters, etc.). | Number | participants |
|
| Race/Ethnicity | Number | participants |
|
| Refractive Error in Amblyopic Eye (spherical equivalent/diopters) | Spherical equivalent in diopters defined from cycloplegic refraction as sphere plus half the cylinder value | Number | participants |
|
| Refractive Error in Fellow Eye (spherical equivalent/diopters) | Spherical equivalent in diopters defined from cycloplegic refraction as sphere plus half the cylinder value | Number | participants |
|
| Mean (SD) Distance Visual Acuity in Amblyopic Eye | Visual acuity was measured with the electronic early treatment diabetic retinopathy study (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. | Mean | Standard Deviation | letters |
|
| Mean (SD) Distance Visual Acuity in Fellow Eye | Visual acuity was measured with the electronic early treatment diabetic retinopathy study (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. | Mean | Standard Deviation | letters |
|
| Mean (SD) Intereye Acuity Difference | Visual acuity was measured with the electronic early treatment diabetic retinopathy study (E-ETDRS) method and resulted in a letter score in each eye that could range from 0 to 97 letters. Intereye difference calculated as the difference in letters between the sound eye and amblyopic eye (positive difference indicates sound eye better). | Mean | Standard Deviation | letters |
|
| Mean (SD) Spherical Equivalent Refractive Error in Amblyopic Eye | Spherical equivalent in diopters defined from cycloplegic refraction as sphere plus half the cylinder value | Mean | Standard Deviation | diopters |
|
| Mean (SD) Spherical Equivalent Refractive Error in Fellow Eye | Spherical equivalent in diopters defined from cycloplegic refraction as sphere plus half the cylinder value | Mean | Standard Deviation | diopters |
|
| Weight in Kilograms | Median | Full Range | kilograms |
|
| Higher Dose 0.76 mg Levodopa/Carbidopa |
Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid combined with 2 hours of daily patching, with a rapid taper of medication before a primary outcome exam. |
|
|
| Primary | Mean Amblyopic Eye Visual Acuity Letter Scores at 9 Weeks After Starting Levodopa | Visual acuity was measured with the electronic early treatment diabetic retinopathy study (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. | Posted | Mean | Standard Deviation | letters | 9 weeks after starting levodopa |
|
|
|
| Primary | Distribution of Change in Amblyopic Eye Visual Acuity Scores at 9 Weeks After Starting Levodopa | Visual acuity was measured with the electronic early treatment diabetic retinopathy study (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 the best. A difference was calculated as the difference in letters between baseline and outcome with positive difference indicating improvement in acuity. | Posted | Number | participants | baseline to 9 weeks |
|
|
|
| Secondary | Distribution of Amblyopic Eye Visual Acuity Letter Scores at 4 Weeks After Enrollment | Visual acuity was measured with the electronic early treatment diabetic retinopathy study (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 the best. Letter scores are presented as Snellen Equivalents for presentation (i.e. 20/20 includes those with letter scores between 83 and 87 letters, 20/25 includes those with letter scores between 78 to 82 letters, etc.). | Posted | Number | participants | 4 weeks after enrollment |
|
|
|
| Secondary | Mean Amblyopic Eye Visual Acuity Letter Scores at 4 Weeks Post Enrollment | Visual acuity was measured with the electronic early treatment diabetic retinopathy study (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 the best. | Posted | Mean | Standard Deviation | letters | 4 weeks after enrollment |
|
|
|
| Secondary | Distribution of Amblyopic Eye Visual Acuity Letter Scores at 10 Weeks After Stopping Levodopa | Visual acuity was measured with the electronic early treatment diabetic retinopathy study (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 the best. Letter scores are presented as Snellen Equivalents for presentation (i.e. 20/20 includes those with letter scores between 83 and 87 letters, 20/25 includes those with letter scores between 78 to 82 letters, etc.). | Posted | Number | participants | 10 weeks after stopping levodopa |
|
|
|
| Secondary | Mean Amblyopic Eye Visual Acuity Letter Scores at 10 Weeks After Stopping Levodopa | Visual acuity was measured with the electronic early treatment diabetic retinopathy study (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 the best. | Posted | Mean | Standard Deviation | letters | 10 weeks after stopping levodopa |
|
|
|
| Primary | Mean Change in Amblyopic Eye Visual Acuity Letter Scores at 9 Weeks After Starting Levodopa | Visual acuity was measured with the electronic early treatment diabetic retinopathy study (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 the best. A difference was calculated as the difference in letters between baseline and outcome with positive difference indicating improvement in acuity. | Posted | Mean | Standard Deviation | letters | baseline to 9 weeks |
|
|
|
|
| Primary | Tolerability of Study Medication-Adverse Event Reporting | Number of adverse events reported throughout entire study. | Posted | Number | events | 24 weeks |
|
|
|
| Secondary | Distribution of Change in Amblyopic Eye Visual Acuity Scores at 4 Weeks Post Enrollment | Visual acuity was measured with the electronic early treatment diabetic retinopathy study (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 the best. A difference was calculated as the difference in letters between baseline and outcome with positive difference indicating improvement in acuity. | Posted | Number | participants | enrollment to 4 weeks |
|
|
|
| Secondary | Mean Change in Amblyopic Eye Visual Acuity Letter Scores at 4 Weeks Post Enrollment | Visual acuity was measured with the electronic early treatment diabetic retinopathy study (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 the best. A difference was calculated as the difference in letters between baseline and outcome with positive difference indicating improvement in acuity. | Posted | Mean | Standard Deviation | letters | enrollment to 4 weeks |
|
|
|
| Secondary | Distribution of Change in Amblyopic Eye Visual Acuity Scores at 10 Weeks After Stopping Levodopa | Visual acuity was measured with the electronic early treatment diabetic retinopathy study (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters. A difference was calculated as the difference in letters between baseline and outcome with positive difference indicating improvement in acuity. | Posted | Number | participants | baseline to 10 weeks after stopping levodopa |
|
|
|
| Secondary | Mean Change in Amblyopic Eye Visual Acuity Letter Scores at 10 Weeks After Stopping Levodopa | Visual acuity was measured with the electronic early treatment diabetic retinopathy study (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 the best. A difference was calculated as the difference in letters between baseline and outcome with positive difference indicating improvement in acuity. | Posted | Mean | Standard Deviation | letters | baseline to 10 weeks after stopping levodopa |
|
|
|
| 0 |
| 16 |
| 8 |
| 16 |
| EG001 | Higher Dose 0.76 mg Levodopa/Carbidopa | Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid combined with 2 hours of daily patching, with a rapid taper of medication before a primary outcome exam. | 0 | 17 | 11 | 17 |
| Cold/Upper Respiratory Infection/Cough | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Rash | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Flu | General disorders | Systematic Assessment |
|
| Nausea/Vomiting | Gastrointestinal disorders | Systematic Assessment |
|
| Fatique/Sleepiness | General disorders | Systematic Assessment |
|
| Dizziness/Light-headedness | General disorders | Systematic Assessment |
|
| Conjunctivitis | Eye disorders | Systematic Assessment |
|
| Muscle Pain | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Stomache Ache | Gastrointestinal disorders | Systematic Assessment |
|
| Ear Ache | Ear and labyrinth disorders | Systematic Assessment |
|
| Fever | General disorders | Systematic Assessment |
|
| Loss of Appetite | General disorders | Systematic Assessment |
|
| Nightmare | General disorders | Systematic Assessment |
|
| Knee Injury | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Sinus Infection | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Weight Loss | Metabolism and nutrition disorders | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | Systematic Assessment |
|
| Finger injury | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Pulled Muscle | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
Not provided
Not provided
| D012678 | Sensation Disorders |
| D009461 | Neurologic Manifestations |
| D005128 | Eye Diseases |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| 5 to 9 letters worse |
|
| Within plus or minus 4 letters |
|
| 5 to 9 letters better |
|
| 10 to 14 letters better |
|
| >=15 letters better |
|
| 20/80 (53 to 57) |
|
| 20/63 (58 to 62) |
|
| 20/50 (63 to 67) |
|
| 20/40 (68-72 letters) |
|
| 20/32 (73 to 77 letters) |
|
| 20/80 (53 to 57) |
|
| 20/63 (58 to 62) |
|
| 20/50 (63 to 67) |
|
| 20/40 (68-72 letters) |
|
| 20/32 (73 to 77 letters) |
|
| Rash |
|
| Flu |
|
| Nausea/Vomiting |
|
| Fatigue/Sleepiness |
|
| Dizziness/light-headedness |
|
| Conjunctivitis |
|
| Muscle pain |
|
| Stomach ache |
|
| Ear ache |
|
| Fever |
|
| Loss of appetite |
|
| Nightmare |
|
| Knee injury |
|
| Sinus infection |
|
| Weight loss |
|
| Constipation |
|
| Finger injury |
|
| Pulled muscle |
|
| 5 to 9 letters worse |
|
| Within plus or minus 4 letters |
|
| 5 to 9 letters better |
|
| 10 to 14 letters better |
|
| >=15 letters better |
|
| 5 to 9 letters worse |
|
| Within plus or minus 4 letters |
|
| 5 to 9 letters better |
|
| 10 to 14 letters better |
|
| >=15 letters better |
|